Affimed NV (STU:A28A)
€ 3.5 -0.04 (-1.13%) Market Cap: 55.46 Mil Enterprise Value: 34.65 Mil PE Ratio: 0 PB Ratio: 1.94 GF Score: 36/100

Q2 2021 Affimed NV Earnings Call Transcript

Sep 08, 2021 / 12:30PM GMT
Release Date Price: €56.95 (+1.24%)
Operator

Good day, and welcome to Affimed's Second Quarter 2021 Financial Results and Corporate Update Conference Call. (Operator Instructions)

As a reminder, today's conference call is being recorded.

I'd now like to introduce your host for today's conference call, Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR

Thank you, Liz. I'd like to also welcome you all for joining us today for our second quarter 2021 results and operational update call. Before we begin, I'd like to remind everyone that we issued the relevant press release earlier today and that it can be found on the Investor Relations section of our website.

On the call today, we have the following members of our management team: Dr. Adi Hoess, our Chief Executive Officer; Andreas Harstrick, our Chief Medical Officer; Arndt Schottelius, our Chief Scientific Officer; Wolfgang Fischer, our Chief Operating Officer; and Angus Smith, our Chief Financial Officer. The whole team will be available for the Q&A

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot